Form 4: Srinivas Akkaraju Reports Acquisition of vTv Therapeutics Securities

Srinivas Akkaraju, a director and 10% owner of vTv Therapeutics Inc., reports acquiring Class A Common Stock and Pre-Funded Warrants.

Summary

• On February 27, 2024, Srinivas Akkaraju acquired 224,732 shares of Class A Common Stock at $11.81 per share.
• Akkaraju also acquired 833,693 Pre-Funded Warrants exercisable for Class A Common Stock at $0.01 per warrant.
• These securities are held by Samsara BioCapital, L.P., of which Samsara BioCapital GP, LLC is the general partner.
• Akkaraju has voting and investment power over the securities held by Samsara LP and may be deemed to beneficially own these securities.
• The Pre-Funded Warrants have no expiration date and are exercisable at any time after issuance, subject to a 9.99% ownership limitation.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard SEC filing reporting a transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. This filing indicates changes in Akkaraju's ownership stake in vTv Therapeutics.

Stakeholder Impact

• The acquisition of shares and warrants by a director and significant shareholder could be viewed positively by other shareholders, signaling confidence in the company's future.

Key Dates